Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys

Anais da Academia Brasileira de Ciencias

Volumn 80, Issue 2, 2008, Pages 311-321

  Trindade, Gisela F ^a   Marchevsky, Renato S ^b   De Fillipis, Ana M B ^a   Nogueira, Rita M R ^a   Bonaldo, Myrna C ^a   Acero, Pedro C ^a   Caride, Elena ^b   Freire, Marcos S ^b   Galler, Ricardo ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

Attenuation; Dengue; Real time RT PCR; Replication; Vaccine; Yellow fever

Indexed keywords

DENGUE VIRUS; FLAVIVIRUS; MACACA MULATTA; YELLOW FEVER VIRUS; YELLOW FEVER VIRUS (STRAIN 17D);

EID: 44849098231     PISSN: 00013765     EISSN: 16782690     Source Type: Journal    
DOI: 10.1590/s0001-37652008000200009     Document Type: Article

References (35)

1. BAE H-G, NITSCHE A, TEICHMANN A, BIEL SS AND NIEDRIG M. 2003. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. J Virol Methods 101: 185-191.
2. BENTE DA AND RICO-HESSE R. 2006. Models of dengue virus infection. Drug Discovery Today 3: 97-103.
3. BLANKY JE JR, MATRO JM, MURPHY BR AND WHITE-HEAD SS. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79: 5516-5528.
4. CALISHER CH, KARABATSOS N, DARYMPLE JM, SHOPE RE, PORTERFIELD JS, WESTAWAY EG AND BRANDT WE. 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70: 37-43.
5. DURBIN AP ET AL. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 65: 405-413.
6. DROSTEN C, GOTTIG S, SCHILLING S, ASPER M, PANNING M, SCHMITZ H AND GUNTHER S. 2002. Rapid detection and quantification of RNA of ebola and marburg viruses, lassa virus, crimean-congo hemorrhagic fever virus, rift valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40: 2323-2330.
7. EDELMAN R, WASSERMAN SS, BODISON SA, PUTNAK RJ, ECKELS KH, KANESA-THASAN N, VAUGHN DW, INNIS BL AND SUN W. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (Suppl 6): 48-60.
8. GALLER R, MARCHEVSKY RS, CARIDE E, ALMEIDA LFC, YAMAMURA AMY, JABOR AV, MOTTA MCA, BONALDO MC, COUTINHO ESF AND FRLIRE MS. 2005. Recombinant yellow fever 17D-dengue type 2 virus: attenuation and immunogenicity for rhesus monkeys. Braz J Med Biol Res 38: 1835-1846.
9. GUBLER DJ. 2004. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 27: 319-330.
10. GUIRAKHOO F, WELTZIN R, CHAMBERS TJ, ZHANG ZX, SOIKH K, RATTERREE M, ARROYO J, GEORGAKOPOULUS K, CATALAN J AND MONATH TP. 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485.
11. GUIRAKHOO F ET AL. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298: 146-159.
12. GUIRAKHOO F ET AL. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine: phase I clinical trial for safety and immunogenicity. Human Vaccines 2: 60-67.
13. HOUNG HH, CHEN RC, VAUGHN DW AND KANESATHASAN N. 2001. Development of a fluorogenic RTPCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' noncoding sequences. J Virol Methods 95: 19-32.
14. KALITA J AND MISRA UK. 2006. EEG in dengue virus infection with neurological manifestations: a clinical and CT/MRI correlation. ClinNeurophysiol 117: 2252-2256.
15. KANESA-THASAN N ET AL. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 30:3179-3188.
16. LAI CJ AND MONATH TP. 2003. Chimericflaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res 61: 469-509.
17. LINDENBACH BD AND RICH CM. 2001. Flaviviridae: The viruses and their replication. In: FIELDS BN, KNIPE DM, HOWLEY PM (Eds), Field's Virology, Lippincott Williams and Wilkins, Phildelphia, p. 991-1041.
18. MARCHEVSKY RS, FREIRE MS, COUTINHO ESF AND GALLER R. 2003. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316: 55-63.
19. MARCHEVSKY RS, LEAL ML, HOMMA A, COUTINHO ESF, CAMACHO LAB, JABOR AV, GALLLR R AND FREIRE MS. 2006. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. Biologicals 34: 191-197.
20. MONATH TP. 2003. Yellow fever vaccine. In: PLOTKIN SA, ORENSTEIN WD (Eds), Vaccines, WB Saunders, USA, p. 1095-1176.
21. MONATH TP, BRINKER KR, CHANDLER FW, KEMP GE AND CROPP CB. 1981. Pathophysiologic correlations in a rhesus monkey model of yellow fever. Am J Trop Med Hyg 30: 431-443.
22. POERSCH CO, PAVONI DP, QUEIROZ MH, BORBA L, GOLDENBERG S, SANTOS CN AND KRIEGER MA. 2005. Dengue virus infections: comparison of methods for diagnosing the acute disease. J Clin Virol 32: 272-277.
23. PUIG M, MIHALIK K, YU MW, FEINSTONE SM AND MAJOR ME. 2002. Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCT assay. J Virol Methods 105: 253-263.
24. PUTNAK JR ET AL. 2005. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in rhesus macaque model. Vaccine 23: 4442-4452.
25. RUSSEL PK AND NISALAK A. 1967. Dengue virus identification by the plaque redution neutralization test. J Immunol 99: 291-296.
26. SABCHAREON A ET AL. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272.
27. SABCHAREON A ET AL. 2004. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99-109.
28. SOARES CN, FARIA LC, PERALTA JM, DE FREITAS MR AND PUCCIONI-SOHLER M. 2006. Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. J Neurol Sci 249: 19-24.
29. SOLOMON T ET AL. 2000. Neurological manifestations of dengue infection. Lancet 355: 1053-1059.
30. SUN W ET AL. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69 (Suppl. 6): 24-31.
31. SUN W, NISALAK A, GETTAYACAMIN M, ECKELS KH, PUTNAK JR, VAUGHN DW, INNIS BL, THOMAS SJ AND ENDY TP. 2006. Protection of rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 193: 1658-1665.
32. THEILER M. 1951. The virus. In: STRODEGK(Ed). Yellow Fever. New York, McGraw-Hill Book Company, p. 39-138.
33. VAUGHN DW, GREEN S, KALAYANAROOJ S, INNIS BL, NIMMANNITYA S, SUNTAYAKORN S, ROTHMAN AL, ENNIS FA AND NISALAK A. 1997. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 176: 322-330.
34. VAUGHN DW, GREEN S, KALAYANAROOJ S, INNIS BL, NIMMANNITYA S, SUNTAYAKORN S, ROTHMAN AL, ENNIS FA AND NISALAK A. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2-9.
35. WORLD HEALTH ORGANIZATION. 1998. Requirements for yellow fever vaccine. WHO Tech Rep Ser 872: 31-68.